140 related articles for article (PubMed ID: 12390813)
1. [Relationship between insulin-degrading enzyme activity and insulin sensitivity in cell model of insulin-resistance].
Li CZ; Zhang SH; Shu CD; Ren W
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):151-4. PubMed ID: 12390813
[TBL] [Abstract][Full Text] [Related]
2. [Effects of chloroquine on insulin sensitivity in insulin-resistant rats].
Li C; Zhang S; Shu C
Zhonghua Yi Xue Za Zhi; 1999 Nov; 79(11):867-9. PubMed ID: 11715496
[TBL] [Abstract][Full Text] [Related]
3. Insulin-degrading enzyme hydrolyzes ATP.
Del Carmen Camberos M; Cresto JC
Exp Biol Med (Maywood); 2007 Feb; 232(2):281-92. PubMed ID: 17259336
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation.
Cordes CM; Bennett RG; Siford GL; Hamel FG
Biochem Pharmacol; 2009 Mar; 77(6):1064-73. PubMed ID: 19154729
[TBL] [Abstract][Full Text] [Related]
5. Insulin acts intracellularly on proteasomes through insulin-degrading enzyme.
Duckworth WC; Bennett RG; Hamel FG
Biochem Biophys Res Commun; 1998 Mar; 244(2):390-4. PubMed ID: 9514933
[TBL] [Abstract][Full Text] [Related]
6. Regulation of protein degradation by insulin-degrading enzyme: analysis by small interfering RNA-mediated gene silencing.
Fawcett J; Permana PA; Levy JL; Duckworth WC
Arch Biochem Biophys; 2007 Dec; 468(1):128-33. PubMed ID: 17964527
[TBL] [Abstract][Full Text] [Related]
7. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures.
Lynch JA; George AM; Eisenhauer PB; Conn K; Gao W; Carreras I; Wells JM; McKee A; Ullman MD; Fine RE
J Neurosci Res; 2006 May; 83(7):1262-70. PubMed ID: 16511862
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels.
Radulescu RT; Hufnagel C; Luppa P; Hellebrand H; Kuo WL; Rosner MR; Harbeck N; Giersig C; Meindl A; Schmitt M; Weirich G
Int J Oncol; 2007 Jan; 30(1):73-80. PubMed ID: 17143514
[TBL] [Abstract][Full Text] [Related]
9. The proteolytic activity of insulin-degrading enzyme: a mass spectrometry study.
Grasso G; Rizzarelli E; Spoto G
J Mass Spectrom; 2009 May; 44(5):735-41. PubMed ID: 19127548
[TBL] [Abstract][Full Text] [Related]
10. Insulin-degrading enzyme.
Authier F; Posner BI; Bergeron JJ
Clin Invest Med; 1996 Jun; 19(3):149-60. PubMed ID: 8724818
[TBL] [Abstract][Full Text] [Related]
11. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Farris W; Leissring MA; Hemming ML; Chang AY; Selkoe DJ
Biochemistry; 2005 May; 44(17):6513-25. PubMed ID: 15850385
[TBL] [Abstract][Full Text] [Related]
12. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.
Zhao Z; Xiang Z; Haroutunian V; Buxbaum JD; Stetka B; Pasinetti GM
Neurobiol Aging; 2007 Jun; 28(6):824-30. PubMed ID: 16769157
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone inhibits insulin binding to insulin-degrading enzyme and cytosolic insulin-binding protein p82.
Harada S; Smith RM; Hu DQ; Jarett L
Biochem Biophys Res Commun; 1996 Jan; 218(1):154-8. PubMed ID: 8573122
[TBL] [Abstract][Full Text] [Related]
14. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.
Hamel FG; Fawcett J; Tsui BT; Bennett RG; Duckworth WC
Diabetes Obes Metab; 2006 Nov; 8(6):661-8. PubMed ID: 17026490
[TBL] [Abstract][Full Text] [Related]
15. Hyperinsulinemia caused by dexamethasone treatment is associated with reduced insulin clearance and lower hepatic activity of insulin-degrading enzyme.
Protzek AO; Rezende LF; Costa-Júnior JM; Ferreira SM; Cappelli AP; de Paula FM; de Souza JC; Kurauti MA; Carneiro EM; Rafacho A; Boschero AC
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):1-8. PubMed ID: 26386462
[TBL] [Abstract][Full Text] [Related]
16. Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates.
Miners JS; Kehoe PG; Love S
J Neurosci Methods; 2008 Mar; 169(1):177-81. PubMed ID: 18221786
[TBL] [Abstract][Full Text] [Related]
17. Regulation of insulin degradation: expression of an evolutionarily conserved insulin-degrading enzyme increases degradation via an intracellular pathway.
Kuo WL; Gehm BD; Rosner MR
Mol Endocrinol; 1991 Oct; 5(10):1467-76. PubMed ID: 1775131
[TBL] [Abstract][Full Text] [Related]
18. Insulin degrading enzyme is expressed in the human cerebrovascular endothelium and in cultured human cerebrovascular endothelial cells.
Gao W; Eisenhauer PB; Conn K; Lynch JA; Wells JM; Ullman MD; McKee A; Thatte HS; Fine RE
Neurosci Lett; 2004 Nov; 371(1):6-11. PubMed ID: 15500957
[TBL] [Abstract][Full Text] [Related]
19. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Du J; Zhang L; Liu S; Zhang C; Huang X; Li J; Zhao N; Wang Z
Biochem Biophys Res Commun; 2009 Jun; 383(4):485-90. PubMed ID: 19383491
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
Ciaccio C; Tundo GR; Grasso G; Spoto G; Marasco D; Ruvo M; Gioia M; Rizzarelli E; Coletta M
J Mol Biol; 2009 Feb; 385(5):1556-67. PubMed ID: 19073193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
